Abstract:Background: The spread of drug-resistant HIV-1 strains has increased the difficulty of preventing and controlling HIV in Hebei, China. Objective: We aimed to assess the prevalence of HIV-1 drug-resistant strains in this area. Methods: We collected plasma samples from HIV/AIDS patients undergoing antiviral treatment in the eleven prefectures in Hebei using stratified sampling. We used in-house assays to assess HIV-1 drug resistance (DR) based on pol gene sequences and assessed the distribution of DR among subtypes, transmission routes, and prefectures. Results: A total of 536 pol gene sequences, belonging to subtype B (68.7%), CRF01_AE (24.4%), subtype C (5.2%), and CRF07_BC (1.7%), were successfully obtained from 601 samples. Of these, 29.3% of strains were resistant to at least one antiretroviral drug listed in the HIV Drug Resistance Database. The most frequent mutation sites were M184V/I (20.7%), K103N/S (11.2%), and Y181C (10.6%), which mainly cause high-level resistance to 3TC, NVP, and EFV, respectively, and the rates of highlevel resistance to these drugs were 86.7%, 72.7%, and 51.6%, respectively. Additionally, the distributions of M184V/I, D67N, L210W, Q151M, and M230L were significantly different in all four transmission routes, and the prevalence of HIV-1 DR was significantly different among the eleven Hebei prefectures. Furthermore, the duration of therapy, genotype, CD4+ cell count, initial therapeutic regimen, and change of therapeutic regimen were all significantly related to the development of DR. Conclusion: To minimize the impact of the development of DR in HIV/AIDS patients, HIV-1 DR should be monitored and treatment regimens should be updated appropriately.

Prevalence of HIV-1 Drug Resistance among HAART-Virological Failure Patients Between 2011 and 2012 in Hebei, China.